{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Duration of MRD negativity for participants achieving MRD negativity is defined as the time from the date of first documentation of MRD negativity to the first documentation of MRD positivity or confirmed progressive disease, whichever occurs first. It will be calculated for participants achieving MRD negativity only. No participants had sCR or CR in Phase 1 thus the overall number of participants analyzed is zero.","groups":[{"description":"Participants received modakafusp alfa 80 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 60 weeks.","id":"OG000","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 80 mg + Daratumumab"},{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 48 weeks.","id":"OG001","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 120 mg + Daratumumab"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 36 weeks.","id":"OG002","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 240 mg + Daratumumab"},{"description":"Participants were planned to receive modakafusp alfa at dose level 1 (DL1) \\[selected from Phase 1 Dose Escalation\\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.","id":"OG003","title":"Phase 2a Dose Finding: Modakafusp Alfa (DL1) + Daratumumab"},{"description":"Participants were planned to receive modakafusp alfa at dose level 2 (DL2) \\[selected from Phase 1 Dose Escalation\\] with daratumumab SC 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression.","id":"OG004","title":"Phase 2a Dose Finding: Modakafusp Alfa (DL2) + Daratumumab"}],"populationDescription":"Only participants who had a confirmed stringent CR (sCR) or complete response (CR) were to be analyzed for this outcome measure. After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with Phase 2a due to strategic reasons. Thus, no participants were enrolled for Phase 2a \\& no data was collected for this outcome measure due to study termination.","reportingStatus":"POSTED","timeFrame":"Up to 15.9 months","title":"Phase 1 and Phase 2a: Duration of Measurable [Minimal] Residual Disease (MRD) Negativity","type":"SECONDARY"}